header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

ANTIBIOTIC-MODIFIED TI6AL4V IMPLANT INHIBITS BACTERIAL COLONIZATION UNDER PHYSIOLOGICAL CONDITIONS



Abstract

INTRODUCTION: We have previously demonstrated the efficacy of a modified Ti-surface tethered with antibiotics in preventing bacterial colonization. It is not known if coverage of this surface with serum or other physiological material may hinder the bactericidal properties of such a surface.. The in vitro activity and efficacy of such a surface against S. aureus and S. epidermidis was tested following coverage of the surface with serum.

METHODS: Vancomycin was coupled to Ti6Al4V pins by aminopropylation, linker addition, and vancomycin coupling (VancTi). Bactericidal activity was tested in solutions of bacteria (Ci=1×104cfu/ml) incubated with pins±pre-incubation with fetal bovine serum (FBS). Anti fibronectin and anti-vancomycin antibodies were used to detect surface coating or modification. Bacteria were detected by fluorescent labeling (Syto9) or by direct counting after solubilization.

RESULTS: By immunofluorescence, pins were extensively covered with serum fibronectin which did not interfere with the diffuse, intense vancomycin staining. When incubated with S. epidermidis or S. aureus, VancTi showed little colonization compared to control pins (> 95% reduction in cfu).

DISCUSSION: In a physiological environment, implants will be coated with serum proteins. Activity of the VancTi was unaffected by this coating and maintained potent inhibition of bacterial colonization. We have described a surface modification that allows Ti implants to resist colonization and subsequent periprosthetic infection. Such surfaces hold great promise for the prevention and treatment of periprosthetic infections.

Correspondence should be addressed to Ms Larissa Welti, Scientific Secretary, EFORT Central Office, Technoparkstrasse 1, CH-8005 Zürich, Switzerland